Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma

e260 of GF utilization occurred in the first 6 months and > 75% occurred in the first 9 months. BORT cost differentials were driven by higher usage intensity and cost per GF-using patient. Among 393 patients identified with second-line MM, monthly GF costs in the LEN-treated group declined from $211 at treatment initiation to $99 18 months later, while monthly GF costs in the BORT group increased from $364 to $693. Based on the Wilcoxon Rank-sum test, the difference between average GF costs per month across 18+ months after treatment initiation for MM patients was statistically significant ($242, p-value < 0.001) in favor of LEN. Treatment groups were comparable at baseline. Conclusion: BORT is associated with higher monthly GF use and cost during MM treatment, contributing to the significant overall cost disadvantage for BORT vs. LEN-based regimens.